报价延迟最少15分钟:2026/01/07 16:05 EST
盘后时段
|
||||
|
78.08 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
77.84
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.99/2.90
|
|
企业价值
3.46B
|
| 资产负债 |
|
每股账面净值
7.89
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
182.95M
|
|
每股收益
0.29
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
